Recent advances in the development of melanocortin-4 receptor agonists

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 11, 2002, Pages 1631-1638

  Speake, Jason D ^a   Bishop, Michael J ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

7 Transmembrane (7 TM) receptors; Melanocortin 4 receptor (MC4R); Melanocortins; Obesity; Sexual function

Indexed keywords

ALPHA INTERMEDIN; ALPHA INTERMEDIN DERIVATIVE; AMIDINE; AMINOGUANIDINE; BETA INTERMEDIN; CORTICOTROPIN; DRUG VEHICLE; GAMMA INTERMEDIN; GUANIDINE DERIVATIVE; HORMONE RECEPTOR STIMULATING AGENT; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 4 RECEPTOR AGONIST; MELANOCORTIN RECEPTOR; MELANOTAN 1; MELANOTAN 2 DERIVATIVE; METAL DERIVATIVE; N ACETYLNORLEUCYLASPARTYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHYLLYSINE 2,7 CYCLIC AMIDE; PEPTIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

BODY WEIGHT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG RESEARCH; DRUG STRUCTURE; ENERGY BALANCE; FEEDING DISORDER; HUMAN; MEDICAL LITERATURE; MOLECULAR WEIGHT; NONHUMAN; PATENT; PHYSIOLOGY; PUBLICATION; REVIEW; SEXUAL DYSFUNCTION;

EID: 0036848556     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.11.1631     Document Type: Review

References (29)

1. ANDERSSON PM, BOMAN A, SEIFERT E, SKOTTNER A, TORBJORN L: Ligands to the melanocortin receptors. Expert Opin. Ther. Patents (2001) 11(10):1583-1592.
2. MACNEIL DJ, HOWARD AD, GUAN X et al.: The role of melanocortins in body weight regulation: opportunities for the treatment of obesity. Eur. J. Pharmacol. (2002) 440:141-157.
3. ABDEL-MALEK ZA: Melanocortin receptors: their functions and regulation by physiological agonists and antagonists. Cell. Mol. Life Sci. (2001) 58(3):434-441.
4. MARKS DL, CONE RD: Central melanocortins and the regulation of weight during acute and chronic disease. Recent Progress in Hormone Res. (2001) 56:359-375.
5. WIKBERG JES, MUCENIECE R, MANDRIKA I et al.: New aspects on the melanocortins and their receptors. Pharmacol. Res. (2000) 42(5):393-420.
6. VARIOUS AUTHORS: In: The Melanocortin Receptors. Cone RD (Ed), Humana Press, New Jersey, USA (2000).
7. WIKBERG JES: Melanocortin receptors: new opportunities in drug discovery. Expert Opin. Ther. Patents (2001) 11(1):61-76.
8. LU D, WILLARD D, PATEL IR et al.: Agouti protein is an antagonist of the melanocyte-stimulating hormone receptors. Nature (1994) 371:799-802.
9. SHUTTER J, GRAHAM M, KINSEY A et al.: Hypothalamic expression of ART, a novel gene related to agouti, is upregulated in obese and diabetic mutant mice. Genes Dev. (1997) 11:593-602.
10. HUSZAR RRC, LYNCH C, FAIR-HUNTRESS V et al.: Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell (1997) 88:131-141.
11. 4 receptor antagonist (HS014) on melanocortin-induced behavioural effects in rats. Eur. J. Pharmacol. (1998) 362:95-101.
12. 4 receptor antagonist HS014 causes hyperphagia and obesity in rats. NeuroReport (1999) 10:707-711.
13. HAMILTON BS, DOODS HN: Chronic application of MTII in a rat model of obesity results in sustained weight loss. Obes. Res. (2002) 10(3):182-187.
14. DE WIED D, JOLLES J. Neuropeptides derived from proopiocortin: behavioural, physiological, and neurochemical effects. Physiol. Rev. (1982) 62:976-1059.
15. WESSELLS H, LEVINE N, HADLEY ME, DORR R, HRUBY V: Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int. J. Impotence Res. (2000) 12(Suppl. 4):S74-S79.
16. VAN DER PLOEG LHT, MARTIN WJ, HOWARD AD et al.: A role for the melanocortin 4 receptor in sexual function. PNAS (2002) 99(17):11381-11386.
17. YANG Y, FONG TM, DICKINSON CJ et al.: Molecular determinants of ligand binding to the human melanocortin-4 receptor. Biochemistry (2000) 39(48):14900-14911.
18. CHAKI S, NAKAZATO A: Recent advances in feeding suppressing agents: potential therapeutic strategy for the treatment of obesity. Expert Opin. Ther. Patents (2001) 11(11):1677-1692.
19. SHADIAK AM: Novel agonists at melanocortin receptors decrease feeding and body weight in rats. SRI Metabolic Diseases Drug Discovery & Development Summit, Philadelphia, USA (2002).
20. MOLINOFF P, EARLE DC, SHADIACK AM: A double-blind placebo-controlled study to evaluate the safety, pharmacokinetics, and erectogenic effect of subcutaneously administered PT-141 in healthy males. American Urological Association Annual Meeting. Orlando, USA (2002) LB38.
21. BEDNAREK MA, MACNEIL T, TANG R, KALYANI RN, VAN DER PLOEG LHT, WEINBERG DH: Potent and selective peptide agonists of α-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro. Biochem. Biophys. Res. Commun. (2001) 286:641-645.
22. KAVARANA MJ, TRIVEDI D, CAI M et al. Novel cyclic templates of α-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J. Med. Chem. (2002) 45(12):2644-2650.
23. NARGUND RP, SEBHAT I, YE Z et al.: Design and biological profile for selective agonists for the melanocortin subtype-4 receptor. Abstracts of Papers, 222nd ACS National Meeting, Chicago, IL, USA (2001) 639970.
24. 4R) agonists. Gordon Conference on Medicinal Chemistry, Colby Sawyer College (2001).
25. SKOTTNER A, RAPOSINHO P, AUBERT M et al.: Melanocortin 4 receptor agonists and effects on food intake; a multivariate analysis. Keystone Symposium on the Molecular Control of Adipogenesis and Obesity, Keystone, CO, USA (2002) Poster abstract 411.
26. XIAO L, LUO J, TOZZO L et al.: Oral melanocortin 4 receptor agonists for the treatment of obesity and type 2 diabetes. Keystone Symposium on the Molecular Control of Adipogenesis and Obesity Keystone, CO, USA (2002) Poster abstract 310.
27. PILLAI O, DHANIKULA AB, PANCHAGNULA R: Drug delivery: an odyssey of 100 years. Curr. Opin. Chem. Biol. (2001) 5(4):439-446.
28. LI S: Advances in drug delivery and formulation technologies. Frontiers Biotech. Pharm. (2001) 2:189-201.
29. YANCOPOULOS GD: CNTF/Axokine causes weight loss via leptin-like pathway in mice and man. SRI Metabolic Diseases Drug Discovery & Development Summit, Philadelphia, USA (2002).